[go: up one dir, main page]

HUE068603T2 - Módosított IX-es faktor, valamint készítmények, eljárások és alkalmazások sejtekbe, szervekbe és szövetekbe történõ géntranszferhez - Google Patents

Módosított IX-es faktor, valamint készítmények, eljárások és alkalmazások sejtekbe, szervekbe és szövetekbe történõ géntranszferhez

Info

Publication number
HUE068603T2
HUE068603T2 HUE16815331A HUE16815331A HUE068603T2 HU E068603 T2 HUE068603 T2 HU E068603T2 HU E16815331 A HUE16815331 A HU E16815331A HU E16815331 A HUE16815331 A HU E16815331A HU E068603 T2 HUE068603 T2 HU E068603T2
Authority
HU
Hungary
Prior art keywords
organs
tissues
compositions
cells
methods
Prior art date
Application number
HUE16815331A
Other languages
English (en)
Inventor
Katherine A High
Xavier Anguela
Original Assignee
Childrens Hospital Philadelphia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital Philadelphia filed Critical Childrens Hospital Philadelphia
Publication of HUE068603T2 publication Critical patent/HUE068603T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
HUE16815331A 2015-06-23 2016-06-23 Módosított IX-es faktor, valamint készítmények, eljárások és alkalmazások sejtekbe, szervekbe és szövetekbe történõ géntranszferhez HUE068603T2 (hu)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562183599P 2015-06-23 2015-06-23
US201662315453P 2016-03-30 2016-03-30
US201662338315P 2016-05-18 2016-05-18
US201662348781P 2016-06-10 2016-06-10
US201662349572P 2016-06-13 2016-06-13

Publications (1)

Publication Number Publication Date
HUE068603T2 true HUE068603T2 (hu) 2025-01-28

Family

ID=57586246

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE16815331A HUE068603T2 (hu) 2015-06-23 2016-06-23 Módosított IX-es faktor, valamint készítmények, eljárások és alkalmazások sejtekbe, szervekbe és szövetekbe történõ géntranszferhez
HUS2500003C HUS2500003I1 (hu) 2015-06-23 2025-01-07 Módosított IX-es faktor, valamint készítmények, eljárások és alkalmazások sejtekbe, szervekbe és szövetekbe történõ géntranszferhez

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS2500003C HUS2500003I1 (hu) 2015-06-23 2025-01-07 Módosított IX-es faktor, valamint készítmények, eljárások és alkalmazások sejtekbe, szervekbe és szövetekbe történõ géntranszferhez

Country Status (26)

Country Link
US (6) US10799566B2 (hu)
EP (2) EP4378487A3 (hu)
JP (3) JP6831779B2 (hu)
KR (2) KR102415896B1 (hu)
CN (1) CN108138159A (hu)
AU (2) AU2016282781A1 (hu)
CA (1) CA2990193A1 (hu)
CO (1) CO2018000134A2 (hu)
DK (1) DK3313991T3 (hu)
ES (1) ES2989774T3 (hu)
FI (2) FI3313991T3 (hu)
HK (1) HK1252351A1 (hu)
HR (1) HRP20241180T1 (hu)
HU (2) HUE068603T2 (hu)
IL (2) IL256517B2 (hu)
MX (2) MX2018000307A (hu)
NO (1) NO2025003I1 (hu)
NZ (1) NZ738841A (hu)
PE (1) PE20180675A1 (hu)
PH (1) PH12017502424A1 (hu)
PL (1) PL3313991T3 (hu)
PT (1) PT3313991T (hu)
SA (1) SA517390590B1 (hu)
SG (1) SG10202100131WA (hu)
SI (1) SI3313991T1 (hu)
WO (1) WO2016210170A1 (hu)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4234687A2 (en) * 2005-04-07 2023-08-30 The Trustees of the University of Pennsylvania Method of increasing the function of an aav vector
SMT201800468T1 (it) 2008-09-15 2018-11-09 Uniqure Biopharma B V Mutante del polipeptide fattore ix, suoi usi e metodo per la sua produzione
MX367100B (es) * 2012-02-17 2019-08-05 The Children´S Hospital Of Philadelphia Composiciones del vector aav y metodos para su transferencia genetica a celulas, organos y tejidos.
PE20160188A1 (es) 2013-07-22 2016-04-27 Philadelphia Children Hospital Variantes aav y composiciones, metodos y usos para transferencia de gen a celulas, organos y tejidos
CA2966620A1 (en) 2014-11-05 2016-05-12 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
EP4378487A3 (en) 2015-06-23 2024-09-04 The Children's Hospital of Philadelphia Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
AU2017345430B2 (en) 2016-10-20 2024-09-05 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of Fabry disease
CN117801075A (zh) * 2017-03-15 2024-04-02 北卡罗来纳-查佩尔山大学 多倍体腺相关病毒载体及其制备和使用方法
US10550405B2 (en) 2017-03-15 2020-02-04 The University Of North Carolina At Chapel Hill Rational polyploid adeno-associated virus vectors and methods of making and using the same
CN118581121A (zh) * 2017-05-22 2024-09-03 武田药品工业株式会社 用于血友病b的基因疗法的编码具有增加的表达的重组fix的病毒载体
EP3630978A4 (en) * 2017-05-31 2021-03-24 The University of North Carolina at Chapel Hill OPTIMIZED CASSETTES OF GENETIC EXPRESSION OF HUMAN COAGULATION FACTOR IX AND THEIR USE
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
IL271957B2 (en) * 2017-07-10 2024-02-01 Uniqure Ip Bv Means and methods for AAV-based gene therapy
CN119055798A (zh) * 2017-12-19 2024-12-03 阿库斯股份有限公司 Aav介导的治疗性抗体到内耳的递送
BR112021000145A2 (pt) * 2018-07-09 2021-04-06 Flagship Pioneering Innovations V, Inc Composições de fusossoma e usos das mesmas
AU2018434176A1 (en) * 2018-07-27 2021-01-28 Zentrum Für Forschungsförderung In Der Pädiatrie Gmbh Improved concepts for the treatment of genetic disorders with high-capacity plal-generated gold nanoparticles
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
CA3109579A1 (en) * 2018-08-20 2020-02-27 Ucl Business Ltd Factor ix encoding nucleotides
GB2576508A (en) * 2018-08-20 2020-02-26 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
JP2021533805A (ja) * 2018-08-24 2021-12-09 スパーク セラピューティクス インコーポレイテッドSpark Therapeutics, Inc. 最適化されたプロモーター配列、イントロンを含まない発現構築物及び使用方法
WO2020082046A2 (en) 2018-10-18 2020-04-23 Intellia Therapeutics, Inc. Compositions and methods for expressing factor ix
CA3119310A1 (en) * 2018-11-09 2020-05-14 Generation Bio Co. Modified closed-ended dna (cedna) comprising symmetrical modified inverted terminal repeats
MX2021008131A (es) * 2019-01-04 2021-10-13 Sangamo Therapeutics Inc Metodos y composiciones para el tratamiento de la enfermedad de fabry.
US11596671B2 (en) 2019-02-01 2023-03-07 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia B using viral vectors encoding recombinant fix variants with increased expression
EP3826664A4 (en) * 2019-02-06 2022-10-26 Sangamo Therapeutics, Inc. METHOD FOR THE TREATMENT OF TYPE I MUCOPOLYSACCHARIDOSES
CN110205297A (zh) * 2019-05-15 2019-09-06 华北理工大学 一种重组脂肪干细胞及其重组方法
US20220349017A1 (en) * 2019-08-29 2022-11-03 Siemens Healthcare Diagnostics Inc. Reagents and methods for detecting aav shedding
CN111647625A (zh) * 2019-12-25 2020-09-11 深圳三智医学科技有限公司 一种提高人凝血因子ix表达水平的方法
MX2022011777A (es) * 2020-04-07 2022-10-18 Univ Missouri Itrs libres de cpg para la terapia genica aav.
CN113817759B (zh) * 2020-07-10 2023-06-02 南京吉迈生物技术有限公司 修饰的因子ix、组合物、方法及其在基因治疗中的应用
EP4240861A1 (en) 2020-11-03 2023-09-13 Pfizer Inc. Methods for purification of aav vectors by anion exchange chromatography
US20240052322A1 (en) 2020-12-15 2024-02-15 Pfizer Inc. HILIC UPLC-MS Method For Separating and Analyzing Intact Adeno-Associated Virus Capsid Proteins
IL303959A (en) 2020-12-23 2023-08-01 Pfizer Methods for purification of aav vectors by affinity chromatography
US20240307553A1 (en) 2021-04-01 2024-09-19 Pfizer Inc. Pharmaceutical compositions containing adeno-associated viral vector
EP4079860A1 (en) * 2021-04-23 2022-10-26 uniQure biopharma B.V. Methods and means for the prevention and/or treatment of joint damage in hemophilia
JP2024515902A (ja) 2021-04-26 2024-04-10 アレクシオン ファーマ インターナショナル オペレーションズ リミテッド 組織向性が改善されたアデノ随伴ウイルスベクターカプシド
WO2022235614A2 (en) * 2021-05-04 2022-11-10 Regenxbio Inc. Novel aav vectors and methods and uses thereof
EP4359547A1 (en) 2021-06-22 2024-05-01 Pfizer Inc. Production of adeno-associated virus vector in insect cells
US20240287490A1 (en) * 2021-06-23 2024-08-29 Inspirar Limited Composition and method for treating hemophilia b
CN118660710A (zh) 2021-10-20 2024-09-17 罗切斯特大学 用于年龄相关白质损失的竞争性治疗的分离神经胶质祖细胞
IL312000A (en) * 2021-10-27 2024-06-01 Regeneron Pharma Compositions and methods for expression of factor IX for the treatment of hemophilia B
EP4426331A1 (en) 2021-11-02 2024-09-11 University of Rochester Tcf7l2 mediated remyelination in the brain
EP4198134A1 (en) 2021-12-16 2023-06-21 Genethon Gamma-sarcoglycan gene transfer increase using modified itr sequences
WO2023202469A1 (zh) * 2022-04-19 2023-10-26 康霖生物科技（杭州）有限公司 一种用于遗传性凝血因子缺乏病治疗的核酸构建体及其用途
WO2024003687A1 (en) 2022-06-28 2024-01-04 Pfizer Inc. Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
WO2024038365A1 (en) 2022-08-16 2024-02-22 Pfizer Inc. Methods for purification of aav vectors by anion exchange chromatography
TW202426479A (zh) * 2022-10-10 2024-07-01 美商星火治療公司 Apoe基因療法
WO2024091824A1 (en) 2022-10-26 2024-05-02 Ada Forsyth Institute, Inc. Differentiation and reprogramming of chondrocyte
WO2024163747A2 (en) 2023-02-02 2024-08-08 University Of Rochester Competitive replacement of glial cells

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
AU722624B2 (en) 1996-09-06 2000-08-10 Trustees Of The University Of Pennsylvania, The An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6468524B1 (en) 2000-03-22 2002-10-22 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services AAV4 vector and uses thereof
US7351813B2 (en) * 2000-06-20 2008-04-01 The Board Of Trustees Of The Leland Stanford Junior University Liver-specific gene expression cassettes, and methods of use
EP1379281A4 (en) 2001-03-26 2005-05-18 Univ Leland Stanford Junior HELPER-DEPENDENT ADENOVIRUS VECTOR SYSTEM AND METHOD FOR ITS USE
US20080220015A1 (en) 2001-08-03 2008-09-11 Nokad, S.A. Method of modulating neutralizing antibodies formation in mammals, and uses thereof in gene therapy, animal trangenesis and in functional inactivation of endogenous proteins
MX359371B (es) 2001-11-13 2018-09-25 Univ Pennsylvania Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
PT1453547T (pt) 2001-12-17 2016-12-28 Univ Pennsylvania Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
CA2479759A1 (en) 2002-03-22 2003-10-09 Board Of Regents, The University Of Texas System Protamine-adenoviral vector complexes and methods of use
DK1496944T3 (da) 2002-05-01 2008-12-01 Univ Florida Forbedrede rAAV-ekspressionssystemer til genetisk modificering af specifikke sapsid-proteiner
WO2005037226A2 (en) * 2003-10-17 2005-04-28 Georgia Tech Research Corporation Genetically engineered enteroendocrine cells for treating glucose-related metabolic disorders
US8030065B2 (en) * 2004-09-22 2011-10-04 St. Jude Children's Research Hospital Expression of factor IX in gene therapy vectors
EP1799826B1 (en) 2004-09-29 2009-08-12 Children's Memorial Hospital siRNA-MEDIATED GENE SILENCING OF ALPHA SYNUCLEIN
EP4234687A2 (en) 2005-04-07 2023-08-30 The Trustees of the University of Pennsylvania Method of increasing the function of an aav vector
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
WO2008027084A2 (en) 2006-04-28 2008-03-06 The Trustees Of The University Of Pennsylvania Modified aav vectors having reduced capsid immunogenicity and use thereof
EP2848253A1 (en) * 2006-06-19 2015-03-18 Asklepios Biopharmaceutical, Inc. Modified factor VIII and factor IX genes and vectors for gene therapy
AU2009240054B2 (en) 2008-04-22 2013-08-01 Life Sciences Research Partners Vzw Liver-specific nucleic acid regulatory elements and methods and use thereof
SMT201800468T1 (it) 2008-09-15 2018-11-09 Uniqure Biopharma B V Mutante del polipeptide fattore ix, suoi usi e metodo per la sua produzione
GB0911870D0 (en) 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
SG178408A1 (en) * 2009-08-18 2012-03-29 Baxter Int Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
JP5963743B2 (ja) 2010-04-23 2016-08-03 ユニバーシティ オブ マサチューセッツ Ｃｎｓターゲティングａａｖベクターおよびその使用方法
US9816108B2 (en) 2010-04-23 2017-11-14 University Of Florida Research Foundation, Inc. rAAV-guanylate cyclase compositions and methods for treating lebers congenital amaurosis-1 (LCA1)
KR101853405B1 (ko) 2010-10-20 2018-05-02 주식회사 티움바이오 인자 ｉｘ 활성을 갖는 융합 단백질
AU2012340567B2 (en) 2011-11-22 2017-11-23 The Children's Hospital Of Philadelphia Virus vectors for highly efficient transgene delivery
US9434928B2 (en) 2011-11-23 2016-09-06 Nationwide Children's Hospital, Inc. Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
MX367100B (es) 2012-02-17 2019-08-05 The Children´S Hospital Of Philadelphia Composiciones del vector aav y metodos para su transferencia genetica a celulas, organos y tejidos.
KR102063483B1 (ko) 2012-04-18 2020-01-08 더 칠드런스 호스피탈 오브 필라델피아 Ａａｖ 캡시드 변이체를 이용한 고효율 유전자 전달을 위한 조성물 및 방법
AU2013281328B2 (en) 2012-06-27 2017-11-23 Meiragtx Uk Ii Limited Combination for treating an inflammatory disorder
GB201213117D0 (en) 2012-07-24 2012-09-05 Ucl Business Plc Transgene expression
EP3513802B1 (en) 2012-10-26 2023-11-29 Vrije Universiteit Brussel Vector for liver-directed gene therapy of hemophilia and methods and use thereof
US20140271550A1 (en) * 2013-03-14 2014-09-18 The Trustees Of The University Of Pennsylvania Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune Responses
US9700486B2 (en) * 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
MX2016000345A (es) 2013-07-12 2016-06-21 Philadelphia Children Hospital Vector aav y ensayo para anticuerpos neutralizantes anti-aav (virus adenoasociado).
PE20160188A1 (es) * 2013-07-22 2016-04-27 Philadelphia Children Hospital Variantes aav y composiciones, metodos y usos para transferencia de gen a celulas, organos y tejidos
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
DK3270944T3 (da) 2015-03-17 2020-01-27 Univ Brussel Vrije Optimerede leverspecifikke ekspressionssystemer til FVIII og FIX
EP4378487A3 (en) 2015-06-23 2024-09-04 The Children's Hospital of Philadelphia Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
PE20231949A1 (es) * 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
EP3442597A1 (en) 2016-04-15 2019-02-20 The Trustees Of The University Of Pennsylvania Gene therapy for treating hemophilia b

Also Published As

Publication number Publication date
JP7361737B2 (ja) 2023-10-16
AU2016282781A1 (en) 2018-01-18
HUS2500003I1 (hu) 2025-01-28
HK1252351A1 (zh) 2019-05-24
SA517390590B1 (ar) 2022-02-10
US11896652B2 (en) 2024-02-13
JP2018522529A (ja) 2018-08-16
MX2022003116A (es) 2022-04-11
DK3313991T3 (da) 2024-09-09
IL256517A (en) 2018-02-28
CO2018000134A2 (es) 2018-05-21
EP3313991A1 (en) 2018-05-02
PL3313991T3 (pl) 2024-11-04
US20240131126A1 (en) 2024-04-25
EP4378487A2 (en) 2024-06-05
NZ738841A (en) 2024-10-25
US10799566B2 (en) 2020-10-13
CA2990193A1 (en) 2016-12-29
KR102415896B1 (ko) 2022-06-30
EP4378487A3 (en) 2024-09-04
US20200129598A1 (en) 2020-04-30
HRP20241180T1 (hr) 2024-11-22
IL309741A (en) 2024-02-01
JP2021087431A (ja) 2021-06-10
RU2018102242A (ru) 2019-07-25
PE20180675A1 (es) 2018-04-19
WO2016210170A9 (en) 2018-02-15
AU2016282781A9 (en) 2019-08-01
KR20200128215A (ko) 2020-11-11
FI3313991T3 (fi) 2024-10-07
FIC20250001I1 (fi) 2025-01-03
KR20180048580A (ko) 2018-05-10
KR102178322B1 (ko) 2020-11-13
IL256517B2 (en) 2024-06-01
SG10202100131WA (en) 2021-02-25
US20210330763A1 (en) 2021-10-28
BR112017027956A2 (pt) 2018-08-28
US11491213B2 (en) 2022-11-08
RU2018102242A3 (hu) 2020-08-07
US11110153B2 (en) 2021-09-07
ES2989774T3 (es) 2024-11-27
AU2022268345B2 (en) 2025-02-06
JP6831779B2 (ja) 2021-02-17
AU2022268345A1 (en) 2022-12-15
IL256517B1 (en) 2024-02-01
EP3313991A4 (en) 2018-12-05
JP2024009857A (ja) 2024-01-23
SI3313991T1 (sl) 2024-11-29
US20230142320A1 (en) 2023-05-11
US20210008179A1 (en) 2021-01-14
CN108138159A (zh) 2018-06-08
EP3313991B1 (en) 2024-07-17
WO2016210170A1 (en) 2016-12-29
PH12017502424A1 (en) 2018-07-09
US20160375110A1 (en) 2016-12-29
MX2018000307A (es) 2018-05-02
NO2025003I1 (no) 2025-01-07
PT3313991T (pt) 2024-09-27

Similar Documents

Publication Publication Date Title
HUS2500003I1 (hu) Módosított IX-es faktor, valamint készítmények, eljárások és alkalmazások sejtekbe, szervekbe és szövetekbe történõ géntranszferhez
IL289249A (en) Modified Aav and preparations, methods and uses for gene transfer to cells, organs and tissues
HK1245010A1 (zh) 用於治療疾病的遺傳修飾的細胞、組織和器官
HK1205191A1 (en) Aav vector compositions and methods for gene transfer to cells, organs and tissues aav
GB201609438D0 (en) Compositions and methods for cell targeted HPV treatment
EP3240889A4 (en) Compositions and methods for high efficiency in vivo genome editing
EP3331582A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF TRANSPLANTATION CELLS
IL286327A (en) Isolated discogenic cells, methods of using them and methods of preparing them from mammalian tissue
IL240881A0 (en) Expression of the t cell balance gene, preparations, materials and methods for its use
EP3138399A4 (en) Composition for organ, tissue, or cell transplantation, kit, and transplantation method
IL255480B (en) Preparations containing mesenchymal stem cells and their uses
IL246607A0 (en) Improved cellular preparations and methods for cancer treatment
HRP20200145T1 (hr) Spojevi i metode za poboljšavanje transfera virusnog gena u humane hematopoetske stanice
ZA201603270B (en) Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses
IL254732A0 (en) In vitro preservation of therapeutic cells